ABSTRACT
Renal cell carcinoma (RCC) is the most common cancer of newly diagnosed malignancies in the kidney. Elective nephron-sparing surgery (NSS), i.e., partial nephrectomy for patients with a small (generally defined as less than 4 cm in diameter), localized RCC is associated with a low risk of local recurrence (0-3%) and excellent cancer-specific survival rates (90-100%).1,2 Nowadays, many cases of benign and malignant renal tumors are detected at early stage through the wide use of noninvasive imaging techniques such as ultrasonography. NSS is becoming more important than ever.
